ReviewCirculation research2010
Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins.
Review in Circulation research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03208920 (Omega EVAR), which is not on this map. Cited by 174 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Omega EVAR: Use of Fish Oil to Reduce Inflammation During Endovascular Abdominal Aortic Repair.
Who cites it
174 citing papers in PubMed, 1 synthesis or guideline pooled it, 358 citations in OpenAlex.
- Neutrophil-to-lymphocyte ratio predicts hemorrhagic transformation in ischemic stroke: A meta-analysis.Brain and behavior · 2019Pooled it
- The Effect of Low-Dose Acetylsalicylic Acid on Cellular Immune Responses to Experimental Sleep Restriction in Healthy Humans.Neuroimmunomodulation · 2026Trial
- Effects of low-dose acetylsalicylic acid on the inflammatory response to experimental sleep restriction in healthy humans.Brain, behavior, and immunity · 2024Trial
- A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-Associated Tuberculous Meningitis: The LASER-TBM Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Treatment With a Marine Oil Supplement Alters Lipid Mediators and Leukocyte Phenotype in Healthy Patients and Those With Peripheral Artery Disease.Journal of the American Heart Association · 2020Trial
- The Association of Free Fatty Acids and Eicosanoids with the Severity of Depressive Symptoms in Stroke Patients.International journal of molecular sciences · 2020Trial
- Trial
- Trial
- Short-Term, High-Dose Fish Oil Supplementation Increases the Production of Omega-3 Fatty Acid-Derived Mediators in Patients With Peripheral Artery Disease (the OMEGA-PAD I Trial).Journal of the American Heart Association · 2015Trial
- Trial
- Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation.Journal of lipid research · 2014Trial
- Docosahexaenoic Acid and Periodontitis in Adults: A Randomized Controlled Trial.Journal of dental research · 2014Trial
- Resolvin E2 formation and impact in inflammation resolution.Journal of immunology (Baltimore, Md. : 1950) · 2012Trial
- Erythrocyte saturated fatty acids and systemic inflammation in adults.Nutrition (Burbank, Los Angeles County, Calif.)Trial
- Role of Omega-3 Fatty Acids in IgA Nephropathy: An Updated Review of Mechanisms and Evidence.Journal of clinical medicine · 2026Review
- Article
- Next-Generation Redox Mediators: Itaconate, Nitro-Fatty Acids, Reactive Sulfur Species and Succinate as Emerging Switches in Predictive Redox Medicine.Antioxidants (Basel, Switzerland) · 2026Review
- Neutrophil efferocytosis in chronic inflammatory gastrointestinal diseases: mechanistic insights and therapeutic potential.Frontiers in immunology · 2026Review
- Specialized pro-resolving mediators and cancer: news and promises from the other side of the moon.Frontiers in pharmacology · 2026Review
- Anti-Inflammatory Lipid Mediators from Polyunsaturated Fatty Acids: Insights into their Role in Atherosclerosis Microenvironments.Current atherosclerosis reports · 2025Review
114 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The resolution of acute inflammation is a process that allows for inflamed tissues to return to homeostasis. Resolution was held to be a passive process, a concept now overturned with new evidence demonstrating that resolution is actively orchestrated by distinct cellular events and endogenous chemical mediators. Among these, lipid mediators, such as the lipoxins, resolvins, protectins, and newly identified maresins, have emerged as a novel genus of potent and stereoselective players that counter-regulate excessive acute inflammation and stimulate molecular and cellular events that define resolution. Given that uncontrolled, chronic inflammation is associated with many cardiovascular pathologies, an appreciation of the endogenous pathways and mediators that control timely resolution can open new terrain for therapeutic approaches targeted at stimulating resolution of local inflammation, as well as correcting the impact of chronic inflammation in cardiovascular disorders. Here, we overview and update the biosynthesis and actions of proresolving lipid mediators, highlighting their diverse protective roles relevant to vascular systems and their relation to aspirin and statin therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.